Clinical trials: Mild to Moderate COVID-19
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
COVID-19
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
- Trial name
- NCT04501783
- Testing
- Favipiravir, Standard of care (SOC), standard concomitant therapy
- Where
- 10 sites in Russia
- Volunteers
- 168 people
- Sponsor
- R-Pharm
Covid19
Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients
COVID-19 is considered an ongoing international global health problem which already caused 12 million confirmed cases. No specific effective treatment has been identified so far, and available supportive therapies are intended…
- Trial name
- NCT04475120
- Testing
- liposomal lactoferrin, SOC therapy
- Where
- Italy
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of Rome Tor Vergata
COVID-19
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads…
- Trial name
- NCT04681079
- Testing
- albuterol sulfate (MDI), albuterol sulfate (nebulizer)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Theravance Biopharma
Mild-to-Moderate COVID-19
A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function
This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.
- Trial name
- NCT04486482
- Testing
- KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- Kaleido Biosciences
SARS-COV-2 Infections, COVID-19
Fight COVID-19 Trial
A 6-Week Prospective, Open label, Randomized, in Multicenter Study of, Oseltamivir 300mg per day plus Hydroxychloroquine 800 mg per day versus Combination of Lopipinavir 800mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5…
- Trial name
- FIGHT-COVID-19 (NCT04303299)
- Testing
- Oral
- Where
- Thailand
- Volunteers
- 320 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
COVID-19 Infection
Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection
A randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of WPV01 in patients with mild/moderate COVID-19 infection
- Trial name
- NCT05752175
- Testing
- WPV01
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
COVID-19
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been…
- Trial name
- NCT04429711
- Testing
- Ivermectin Oral Product
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Covid19
The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)
Ivermectin, a classical antiparasitic and anti-scabies agent, has demonstrated antiviral activity for a variety of viruses including chikungunya virus, zyka virus and dengue virus and was tested as a potentially effective for…
- Trial name
- NCT04712279
- Testing
- Ivermectin 0.6mg/kg/day, Ivermectin 1.0mg/kg/day, Hydroxychloroquine
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Corpometria Institute
COVID-19
Plasma Immunity of Mild SARS-CoV-2 Omicron and Delta Pandemic in Thailand
The investigators assessed the effect of treatment for COVID and immunity of the volunteers who admitted to the home isolation.
- Trial name
- NCT05328479
- Where
- Thailand
- Volunteers
- 5,181 people, healthy volunteers welcome
- Sponsor
- Mahidol University
COVID-19
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of sotrovimab in pediatric participants from birth to less than (<)18 years old with mild-to-moderate Coronavirus Disease-2019…
- Trial name
- COMET-PACE (NCT05124210)
- Testing
- Sotrovimab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Covid19
Efficacy and Safety of Acetyl L-Carnitine in COVID-19 Patients With Mild-to-Moderate Disease
Different studies showed that acetyl L-Carnitine (LC) positively affects the development and maturation of T lymphocytes, involved in the immune response to viral agents.
- Trial name
- NCT04623619
- Testing
- Acetyl L-Carnitine
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Efficacy and Safety
Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a treatment for outpatients COVID-19 subjects.
- Trial name
- NCT04870606
- Testing
- Proxalutamide (GT0918)
- Where
- 8 sites in United States
- Volunteers
- 733 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
COVID-19, SARS-CoV-2
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from…
- Trial name
- NCT04252664
- Testing
- Remdesivir
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Capital Medical University
Covid19, SARS-CoV Infection
Sargramostim Use in COVID-19 to Recover Patient Health
The purpose of this research is to understand if the study drug, also called sargramostim or Leukine®, can help prevent the worsening of COVID-19 when the study drug is inhaled.
- Trial name
- SCOPE (NCT04707664)
- Testing
- Sargramostim
- Where
- 37 sites in United States, Argentina
- Volunteers
- 600 people
- Sponsor
- Partner Therapeutics, Inc.
COVID, Sars-CoV2
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
- Conditions
- COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
- Trial name
- NCT04419025
- Testing
- N-acetylcysteine
- Where
- 4 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Cambridge Health Alliance
Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus Infection
Fluvoxamine for Adults With Mild to Moderate COVID-19
This clinical trial aims to determine if fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for the sigma-1 receptor, can be used in mild to moderate COVID-19 to prevent the progression to severe COVID-19.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus Infection, Mild to Moderate COVID-19
- Trial name
- NCT04711863
- Testing
- Fluvoxamine
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Asan Medical Center
COVID - 19
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir.
- Trial name
- NCT07157007
- Testing
- Ratutrelvir (83-0060) non-randomised, Paxlovid, Ratutrelvir (83-0060)
- Where
- 15 sites in Australia, South Korea and 2 more
- Volunteers
- 90 people
- Sponsor
- Traws Pharma, Inc.
Coronavirus Infection
Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19
The effective medical treatment against COVID-19 infection is still unknown. Chloroquine phosphate is a well-known antimalarial drug which has been on the market for many years.
- Trial name
- NCT04384380
- Testing
- Hydroxychloroquine Sulfate 200 MG [Plaquenil]
- Where
- Taiwan
- Volunteers
- 33 people
- Sponsor
- Taoyuan General Hospital
COVID-19
A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
The purpose of this clinical trial is to learn about how study medicine (Paxlovid, which contains nirmatrelvir and ritonavir) is changed and eliminated from the body, as well as its safety, and the extent to which side effects…
- Trial name
- NCT05386472
- Testing
- nirmatrelvir, ritonavir
- Where
- 13 sites in United States
- Volunteers
- 25 people
- Sponsor
- Pfizer